These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 18855533)

  • 41. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.
    Tham LS; Goh BC; Nafziger A; Guo JY; Wang LZ; Soong R; Lee SC
    Clin Pharmacol Ther; 2006 Oct; 80(4):346-55. PubMed ID: 17015052
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement.
    Tatarūnas V; Lesauskaitė V; Veikutienė A; Jakuška P; Benetis R
    Medicina (Kaunas); 2011; 47(1):25-30. PubMed ID: 21681008
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
    Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
    Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.
    Shahin MH; Khalifa SI; Gong Y; Hammad LN; Sallam MT; El Shafey M; Ali SS; Mohamed ME; Langaee T; Johnson JA
    Pharmacogenet Genomics; 2011 Mar; 21(3):130-5. PubMed ID: 21228733
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.
    Kim HS; Lee SS; Oh M; Jang YJ; Kim EY; Han IY; Cho KH; Shin JG
    Pharmacogenet Genomics; 2009 Feb; 19(2):103-12. PubMed ID: 19077919
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic and clinical determinants influencing warfarin dosing in children with heart disease.
    Nguyen N; Anley P; Yu MY; Zhang G; Thompson AA; Jennings LJ
    Pediatr Cardiol; 2013 Apr; 34(4):984-90. PubMed ID: 23183958
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans.
    Kimmel SE; Christie J; Kealey C; Chen Z; Price M; Thorn CF; Brensinger CM; Newcomb CW; Whitehead AS
    Pharmacogenomics J; 2008 Feb; 8(1):53-60. PubMed ID: 17325732
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Frequencies of polymorphisms in CYP2C9 and VKORC1 genes influencing warfarin metabolism in Slovak population: implication for clinical practice.
    Krajciova L; Deziova L; Petrovic R; Luha J; Turcani P; Chandoga J
    Bratisl Lek Listy; 2014; 115(9):563-8. PubMed ID: 25318916
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.
    Shalia KK; Doshi SM; Parikh S; Pawar PP; Divekar SS; Varma SP; Mehta R; Doctor T; Shah VK; Saranath D
    J Assoc Physicians India; 2012 Dec; 60():34-8. PubMed ID: 23781667
    [TBL] [Abstract][Full Text] [Related]  

  • 50. VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.
    Oner Ozgon G; Langaee TY; Feng H; Buyru N; Ulutin T; Hatemi AC; Siva A; Saip S; Johnson JA
    Eur J Clin Pharmacol; 2008 Sep; 64(9):889-94. PubMed ID: 18542936
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin.
    Sangviroon A; Panomvana D; Tassaneeyakul W; Namchaisiri J
    Drug Metab Pharmacokinet; 2010; 25(6):531-8. PubMed ID: 20930419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
    Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
    Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.
    Nowak-Göttl U; Dietrich K; Schaffranek D; Eldin NS; Yasui Y; Geisen C; Mitchell LG
    Blood; 2010 Dec; 116(26):6101-5. PubMed ID: 20833980
    [TBL] [Abstract][Full Text] [Related]  

  • 54. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
    Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
    Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population.
    Gaikwad T; Ghosh K; Kulkarni B; Kulkarni V; Ross C; Shetty S
    Eur J Pharmacol; 2013 Jun; 710(1-3):80-4. PubMed ID: 23602689
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations.
    Gan GG; Phipps ME; Lee MM; Lu LS; Subramaniam RY; Bee PC; Chang SH
    Ann Hematol; 2011 Jun; 90(6):635-41. PubMed ID: 21110192
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
    Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
    Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
    Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
    Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
    [TBL] [Abstract][Full Text] [Related]  

  • 60. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.
    Biss TT; Avery PJ; Brandão LR; Chalmers EA; Williams MD; Grainger JD; Leathart JB; Hanley JP; Daly AK; Kamali F
    Blood; 2012 Jan; 119(3):868-73. PubMed ID: 22010099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.